This is a first-time-in-man (FTIM) multicenter, dose escalation study designed to investigate the safety, pharmacokinetics, and pharmacodynamics of AZD5153 in patients with malignant solid tumors or lymphomas. A Bayesian Continual Reassessment Method (CRM) will be applied to approximately 7 cohorts enrolling up to 6 evaluable patients within each cohort.